enVVeno Medical Corporation (NVNO) Fair Value 2026

NVNO · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (51/100)

Quick Summary — As of 2026-08-28, enVVeno Medical Corporation (NVNO) trades at $10.75. QOC: 4.2/10. Value Trap Risk: 51/100 (WARN). 1/13 models active.

Key Facts

Ticker
NVNO
Price
$10.75
Quality Score
4.2/10
Value Trap Risk
51/100
Models Active
1/13
Last Updated
Strength: Dynamic NAV suggests +202.5% upside with 51% confidence
Risk: Value Trap score of 51 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give NVNO?

1 Intrinsic Value Models vs. Current Price ($10.75)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $32.52 +202.5%

All Models Active

All 1 models are displayed above.

What Is enVVeno Medical Corporation (NVNO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for enVVeno Medical Corporation. Trading at $10.75 against an estimated intrinsic value of $32.52, 1 of 1 active models flag meaningful upside of +202.5% at the median.

What Do the Models Say About NVNO?

1 of 13 models are currently active for NVNO. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does NVNO Rank in Medical Devices?

Among 159 Medical Devices stocks, NVNO ranks #143 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, enVVeno Medical Corporation competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is NVNO a Value Trap?

CirclFi's Value Trap algorithm assigns NVNO a score of 51/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for enVVeno Medical Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, enVVeno Medical Corporation is rated at 4.2/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NVNO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NVNO's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy enVVeno Medical Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

POSCPositron CorporationQOC 4.3AMIXAutonomix Medical, Inc.QOC 4.2ADGMAdagio Medical Holdings, Inc.QOC 4.3NUMDNu-Med Plus, Inc.QOC 4.2PMIPicard Medical, Inc.QOC 4.4PFSAProfusa, Inc.QOC 4.1USAQQHSLab, Inc.QOC 8.3NSYSNortech Systems IncorporatedQOC 6.6TLSITriSalus Life Sciences, Inc.QOC 5.7IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: POSC · AMIX · ADGM · NUMD · PMI · PFSA · USAQ · NSYS · TLSI · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to NVNO?

7 companies across all industries closest to NVNO’s Quality of Company score of 4.2/10.

NNAXNew Momentum CorporationQOC 4.2SANASana Biotechnology, Inc.QOC 4.2DSSDSS, Inc.QOC 4.2AGBKAGI IncQOC 4.2SLSRSolaris Resources Inc.QOC 4.2HGASGlobal Gas CorporationQOC 4.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NNAX · SANA · DSS · AGBK · SLSR · HGAS · NVDA

Where Does NVNO Sit in CirclFi's Medical Devices Rankings?

NVNO is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About enVVeno Medical Corporation’s Valuation?

What is enVVeno Medical Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for enVVeno Medical Corporation (NVNO). The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NVNO overvalued or undervalued right now?

At $10.75, 1 of 1 active models suggest NVNO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits enVVeno Medical Corporation's business model in Medical Devices.

What does a Quality of Company score of 4.2 mean for NVNO?

enVVeno Medical Corporation's QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NVNO?

CirclFi analyzes NVNO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is NVNO a value trap in 2026?

enVVeno Medical Corporation's Value Trap score is 51/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns enVVeno Medical Corporation (NVNO) a Quality of Company score of 4.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/NVNO/ · Methodology
Primary sources for this NVNO valuation
  • Financial statements: enVVeno Medical Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001661053) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NVNO as of ; valuations recomputed .